Norepinephrine Kabi (Noradrenaline Tartrate)

Norepinephrine works by directly stimulating α1‑adrenergic receptors, causing peripheral vasoconstriction, and β1‑adrenergic receptors in the heart, increasing contractility and heart rate. This dual action raises systemic vascular resistance and cardiac output, leading to an increase in mean arterial pressure.

The dose of Norepinephrine Kabi is individualized. A qualified prescriber determines the infusion rate based on the patient’s hemodynamic status, target blood pressure, and response to therapy. The medication is administered intravenously under continuous monitoring.

Safety data for norepinephrine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use is only considered when the potential benefit to the mother outweighs any possible risk to the fetus or infant.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative vasopressor is dopamine, which has dose‑dependent receptor activity. Norepinephrine provides more predictable α‑mediated vasoconstriction with less tachyarrhythmia risk, making it the preferred first‑line agent for most cases of septic shock and refractory hypotension.

Norepinephrine Kabi must be stored refrigerated at 2‑8 °C, protected from light. Do not freeze or shake the vial. Before use, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration.

The product is administered by intravenous infusion, preferably through a central venous catheter to reduce extravasation risk. The infusion rate is titrated to achieve the desired blood pressure, with continuous hemodynamic monitoring throughout the treatment.

Serious risks include severe hypertension, cardiac arrhythmias, myocardial ischemia, and peripheral ischemia that can lead to tissue necrosis, especially if extravasation occurs. Immediate recognition and corrective actions are essential to prevent irreversible damage.

Norepinephrine Kabi is contraindicated in patients with known hypersensitivity to norepinephrine or any formulation excipients. Caution is advised in individuals receiving MAO inhibitors, those with uncontrolled hypertension, or patients with peripheral vascular disease where vasoconstriction could worsen ischemia.